The rotavirus vaccine landscape, an update
Mostra el registre complet de l'element
|
Visualització
 (1.646Mb)
|
|
|
|
|
|
|
Cárcamo-Calvo, Roberto; Muñoz Collado, Carlos; Buesa Gómez, Javier; Rodríguez Díaz, Jesús; Gozalbo Rovira, Roberto Vicente
|
|
Aquest document és un/a article, creat/da en: 2021
|
|
|
|
Rotavirus is the leading cause of severe acute childhood gastroenteritis, responsible for more than 128,500 deaths per year, mainly in low-income countries. Although the mortality rate has dropped significantly since the introduction of the first vaccines around 2006, an estimated 83,158 deaths are still preventable. The two main vaccines currently deployed, Rotarix and RotaTeq, both live oral vaccines, have been shown to be less effective in developing countries. In addition, they have been associated with a slight risk of intussusception, and the need for cold chain maintenance limits the accessibility of these vaccines to certain areas, leaving 65% of children worldwide unvaccinated and therefore unprotected. Against this backdrop, here we review the main vaccines under development and the state of the art on potential alternatives. |
|
|
Veure al catàleg Trobes
|
|
|
Aquest element apareix en la col·lecció o col·leccions següent(s)
Mostra el registre complet de l'element
